Impact of centralization of pancreatoduodenectomy on reported radical resections rates in a nationwide pathology database  by Onete, Veronica G. et al.
ORIGINAL ARTICLE
Impact of centralization of pancreatoduodenectomy on reported
radical resections rates in a nationwide pathology database
Veronica G. Onete1,2, Marc G. Besselink2, Chanielle M. Salsbach1,3, Casper H. Van Eijck3, Olivier R. Busch2,
Dirk J. Gouma2, Ignace H. de Hingh 4, Egbert Sieders 5, Cornelis H. Dejong6, Johan G. Offerhaus7,8, I. Quintus Molenaar1
& the Dutch Pancreatic Cancer Group
1Department of Surgery, University Medical Center Utrecht, Utrecht, 2Department of Surgery, Academic Medical Center, Amsterdam, 3Department of
Surgery, Erasmus Medical Center, Rotterdam, 4Department of Surgery, Catharina Hospital Eindhoven, Eindhoven, 5Department of Surgery, University
Medical Center Groningen, Groningen, 6Department of Surgery, University Medical Center Maastricht, Maastricht and NUTRIM School for Nutrition,
Toxicology and Metabolism, Maastricht, 7Department of Pathology, University Medical Center Utrecht, Utrecht, and 8Department of Pathology, Academic
Medical Center Amsterdam, Amsterdam, The Netherlands
Abstract
Background: Centralization of a pancreatoduodenectomy (PD) leads to a lower post-operative
mortality, but is unclear whether it also leads to improved radical (R0) or overall resection rates.
Methods: Between 2004 and 2009, pathology reports of 1736 PDs for pancreatic and peri-ampullary
neoplasms from a nationwide pathology database were analysed. Pre-malignant lesions were excluded.
High-volume hospitals were defined as performing ≥ 20 PDs annually. The relationship between R0
resections, PD-volume trends, quality of pathology reports and hospital volume was analysed.
Results: During the study period, the number of hospitals performing PDs decreased from 39 to 23.
High-volume hospitals reported more R0 resections in the pancreatic head and distal bile duct tumours
than low-volume hospitals (60% versus 54%, P = 0.035) although they operated on more advanced
(T3/T4) tumours (72% versus 58%, P < 0.001). The number of PDs increased from 258 in 2004 to 394
in 2009 which was partly explained by increased overall resection rates of pancreatic head and distal
bile duct tumours (11.2% in 2004 versus 17.5% in 2009, P < 0.001). The overall reported R0 resection
rate of pancreatic head and distal bile duct tumours increased (6% in 2004 versus 11% in 2009,
P < 0.001). Pathology reports of low-volume hospitals lacked more data including tumour stage
(25% versus 15%, P < 0.001).
Conclusions: Centralization of PD was associated with both higher resection rates and more reported
R0 resections. The impact of this finding on overall survival should be further assessed.
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Introduction
Pancreatic adenocarcinoma is the fourth cause of cancer mor-
tality worldwide with nearly 37 000 deaths annually in the
United Stated and 78 000 deaths in the European Union.1 As a
result of the late occurrence of symptoms and the aggressive
tumour biology, less than 20% of patients are suitable candi-
dates for curative surgery.1 The median survival after an R0
resection in these patients is 22 months whereas the survival
for non-resectable patients is only 14 months.2
A number of studies have outlined the relationship between
hospital volume, post-operative mortality, and survival for
patients undergoing surgery for pancreatic and peri-ampullary
neoplasms.3–12 It has been postulated that both short- and
long-term improvements in the outcome of a pancreatic resec-
tion are mainly as a result of improvements in the quality of
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surgery and peri-operative care.7 In patients with pancreatic
ductal adenocarcinoma (PDAC), the ratio of nodal involve-
ment and, to a somewhat lesser extent, the negative resection
margin (R0) are the most important prognostic factors for
long-term survival. It has been suggested that high-volume
hospitals achieve more R0 resections but data are lacking.13–15
Some have suggested that supporting specialities, such as
pathology, may also be of better quality in high-volume hospi-
tals16 but evidence is lacking.
In the Netherlands, a recent nationwide guideline led to the
implementation of a minimum volume of 20 annual proce-
dures for high-risk surgery such as a pancreateoduodenectomy
(PD). A recent analysis demonstrated that in the period 2005
to 2009 centralization occurred in the Netherlands, which
resulted in a decreased post-operative mortality from 9.8% to
5.1%.5 Two additional studies showed that both in the south
and the west of the Netherlands, centralization was associated
with an increased 2-year survival.7,8 It is unknown which
factors have contributed to the increased survival after the cen-
tralization of PD. Does detection bias play a role, or is the
surgical technique somehow improved, leading to an increase
in radical (R0) resections?
The aim of the present work was to analyse the impact of
centralization of PD in the period 2004–2009 in the Nether-
lands on resection rates and reported R0 resections of pancre-
atic and peri-ampullary neoplasms and the quality of
pathology reports.
Methods
The summaries of the pathology reports of all the PDs carried
out in the Netherlands between 2004 and 2009 (6 years) were
obtained from the Dutch nationwide pathology database
(PALGA).17 After 2009, these data were no longer collected for
all hospitals by PALGA. Only patients who underwent a PD for
pancreatic head or a peri-ampullary neoplasm [including pan-
creatic, cholangio, ampullary and duodenum adenocarcinoma,
neuroendocrine tumours, malignant intraductal papillary
mucinous neoplasm (IPMN) and mucinous cystadenocarcino-
ma] were included. PDs carried out for benign or pre-malignant
disease, metastases to the pancreas and peri-ampullary region
(such as renal cell carcinoma) or (auto-immune) pancreatitis,
total pancreatectomies and left-sided pancreatectomies, or
reports which did not mention the tumour type nor the type of
surgery were excluded. Finally, data on the number of pancreas,
ampulla, duodenum and distal bile duct tumours in the Nether-
lands for the period 2004–2009 were collected from the Nether-
lands Cancer Registry managed by the Comprehensive Cancer
Centre Netherlands (CCCNL).18
Variables
The following variables were recorded for each entry: age,
gender, year of surgery, hospital volume, radicality of the
resection, tumour size, histological type, pTN status, tumour
differentiation, ingrowth in surrounding organs and the num-
ber of resected lymph nodes. If the pTN status was not stated
in the report, it was classified according to the AJCC criteria,
7th edition19 but only if enough information, such as ingrowth
in surrounding organs and/or tumour size was available.
If a report presented two different malignant tumours, the
one described as a chance finding was excluded. If a malignant
and a benign tumour were reported on the same specimen, the
malignant tumour was recorded.
The quality of the pathology reports was assessed by measur-
ing the percentage of missing data, such as the pTN status,
tumour diameter, differentiation and radicality of the resection
in the summaries of the pathology reports.
During this study period, neoadjuvant treatment (chemo-
therapy or chemoradiotherapy) was used in less than 1% of
patients.
Definitions
The PD volume of each hospital was assessed per year; centres
with ≥ 20 PDs per year were defined as high-volume hospi-
tals.5 The old definition of resection margins were used as that
was the definition during the study period. According to the
old definition an R0 resection is the absence of cancer cells in
the pancreatic or circumferential resection margin, and an R1
is the presence of microscopic tumour invasion at the resection
margin. If there was any doubt as to the radicality of the exci-
sion or if this was not stated in the report an unknown resec-
tion margin was recorded. Reports using the new definition
were removed.
Tumours were divided according to histological type. Carci-
nomas in situ, and adenomas or neoplasms with high-grade
dysplasia (which were defined as carcinoma in situ), IPMNs
(without invasive growth) and low-grade or moderate dyspla-
sia, pseudo-papillary tumours, and mucinous cystadenomas
were considered were considered to be premalignant. All neu-
roendocrine tumours, indifferent of grade were (arbitrarily)
included in the malignant tumour group. If the histological
type was not named, but the description was that of a malig-
nant tumour, this was marked as unknown. Specimens with
unknown histological type were only included in the calcula-
tions of the trends.
For data analysis, the various histology types of malignant
tumours were pooled according to the anatomic origin of the
tumour: pancreatic head, peri-ampullary and distal bile duct
tumours. Pancreatic head tumours included pancreatic adeno-
carcinoma, invasive IPMN’s and neuroendocrine tumours of
the pancreatic head. Peri-ampullary tumours included all
papilla and duodenum tumours, such as adenocarcinomas,
neuro-endocrine tumours and any remaining histological types
such as sarcomas and lymphomas. Distal bile duct tumours
included adenocarcinomas and neuro-endocrine tumours of
the distal bile ducts. Pancreatic head tumours were analysed
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together with distal bile duct tumours. This was based on the
assumption that when distal bile duct tumours invade the pan-
creas it is often difficult to assess the origin of the primary
tumour (i.e. the pancreas or in the distal bile duct) and as a
result of this patients will often undergo similar surgical proce-
dures.
The pT stage was pooled for all further analysis into four cate-
gories: high stage, low stage, unknown stage (Tx) and NA (not
applicable). The high stage included all T3/T4 tumours, the low
stage included all T1/T2s tumours and NA included several
tumours for which no pTNM staging system was available, such
as lymphomas and gastro-intestinal stroma cell tumours (GIST).
The differentiation of malignant tumours was graded as
poor, moderate, well and unknown. If more than one differen-
tiation degree was stated in the report (i.e. a well to moder-
ately differentiated tumour), the worst differentiation degree
was registered.
Statistical analysis
Continuous non-normally distributed variables were compared
using the Mann–Whitney U-test while normally distributed
variables were compared using the t-test. Categorical variables
were compared with the Chi-squared test. Resectability rates
were calculated by dividing the total number of PDs (R0, R1/R2
and unknown resection margins) by the total number of
tumours per anatomic localization per year as provided by the
Comprehensive Cancer Centre The Netherlands (CCCNL). R0
resectability rates were calculated by dividing the number of R0
resection margins by the total number of tumours per anatomic
localization per year. In order to analyse any changes through-
out the study period, the difference between the total and R0
resection rates in 2004 and 2009 were calculated. This was
achieved by applying the Z-test for the difference between two
percentage means. A two-tailed P-value of < 0.05 was considered
statistically significant. All calculations were carried out in IBM
SPSS Statistics (version 16.0, SPSS Inc, Chicago, IL, USA).
Results
A total of 2180 pathology reports were obtained, out of which
444 (20%) reports were excluded for the following reasons: 81
premalignant tumours (4%), 174 pancreatitis (8%), 65 benign
tumours (3%), 26 reports in which no histological abnormali-
ties were observed (0.01%), 19 metastases (0.9%), 13 pancre-
atic tail tumours (0.6%), 2 gallbladder carcinomas (0.09%),
4 reports that did not mention the tumour type or type of
surgery (0.2%), 60 reports (3%) that stated the resection mar-
gin only according to the new definition, thus leaving a total
of 1736 pathology reports for analysis.
Centralization and trends
During the study period, centralization of pancreatic surgery
occurred: the number of hospitals performing PDs decreased
from 39 to 23 (out of a total of 95 hospitals in the Nether-
lands; 16.7 million inhabitants), whereas the number of high-
volume hospitals increased from 3 to 9. The total volume of
PDs for malignant tumours increased from [250 in 2004 to
389 in 2009 (56% relative increase)]. According to data from
CCCNL, this increase is partly explained by increased overall
resection rates of pancreatic head and distal bile duct tumours
(11.2% in 2004 versus 17.5% in 2009, P < 0.001). During this
period, the overall reported R0 resection rate also increased
from 6.3% in 2004 to 10.5% in 2009, P < 0.001 (Fig. 1).
Comparison of patient and tumour characteristics by hospi-
tal volume are shown in Tables 1 and 2.
High-volume hospitals reported to resect more lymph nodes
per procedure [median (IQR, interquartile range): 10 (6.00–
14.00) versus 7 (4.00–11.00), P < 0.001]. High-volume
hospitals operated on significantly more N1 cancers than low-
volume hospitals (Table 1). This was due to more N1 pancre-
atic head and distal bile duct tumours (61.2% versus 52.2%,
P = 0.002), but not in peri-ampullary tumours.
The resection margin status by hospital type and tumour
subtype are shown in Table 3.
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Figure 1 Annual trends in volume of pancreatoduodenectomy in all malignant tumors per resection margin in the Netherlands
(2004–2009)
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The frequency of missing data from pathology reports by
hospital type is shown in Table 4.
Discussion
This study has shown that during a period where centralization
of pancreatic surgery took place both the overall and reported
R0 resection rates of pancreatic head and distal bile duct
tumours increased. High-volume hospitals more frequently
reported R0 resections in tumours of the pancreatic head and
distal bile duct, even although they operated on more
advanced (T3/T4) tumours. Additionally, high-volume hospi-
tals reported more resected lymph nodes and the pathology
reports were less often incomplete.
These findings are probably best explained by the additional
surgical expertise in high-volume hospitals, despite operating
on more advanced cancers. With additional experience, sur-
geons can resect more tumours and possibly also achieve
higher R0 resection rates. It has previously been shown that
high-volume hospitals are more likely to resect tumours in
pancreatic cancer.20–22 Additionally, Michalski et al.16 showed
that 42% of the patients who were given an initial diagnosis of
unresectability as a result of venous involvement in lower
volume hospitals were resected at a large tertiary referral centre
with a 55% R0 resection rate. This phenomenon probably also
occurred in the Netherlands. Because the pathology reports in
the current study provided too little information no trends in
portomesenteric vein resections could be performed.
Table 1 Characteristics of pancreatoduodenectomies (2004–2009)
for malignant tumours
High-volume
(N = 747)
Low-volume
(N = 989)
P-value
Age, mean (SD) 64.3 (10.39) 64.4 (9.6) 0.831
Gender, male (%) 435 (58.1) 596 (60.1) 0.386
Pancreatic and distal
bile duct tumours,
number (%)
500 (66.9) 653 (66.0) 0.653
Peri-ampullary
tumours, number (%)
229 (30.7) 317 (32.1) 0.535
Unknown tumour type,
number (%)
18 (2.4) 19 (1.90) 0.485
T1/T2, number (%) 144 (19.3) 203 (20.5) 0.519
T3/T4, number (%) 491 (65.7) 538 (54.4) <0.001
Unknown pT Stage,
number (%)
111 (14.9) 245 (24.8) <0.001
Not applicable,
number (%)
1 (0.1) 3 (0.3) 0.466
N0, number (%) 302 (40.4) 450 (45.5) 0.038
N1, number (%) 424 (56.8) 471 (47.6) <0.001
Unknown pN Stage,
number (%)
21 (2.8) 68 (6.9) <0.001
R0, number (%) 512 (68.5) 641 (64.8) 0.103
R1/R2, number (%) 208 (27.8) 297 (30.0) 0.343
Unknown resection
margin, number (%)
27 (3.6) 51 (5.2) 0.125
Poorly differentiated,
number (%)
235 (31.5) 243 (24.6) 0.001
Moderately
differentiated,
number (%)
307 (41.1) 470 (47.5) 0.008
Well differentiated,
number (%)
73 (9.8) 114 (11.5) 0.243
Unknown, number (%) 132 (17.7) 162 (16.4) 0.478
Table 2 Tumour stage and differentiation in subtypes of malignant
tumours
Tumour stage in subtypes of malignant tumours
Pancreatic head and
distal bile duct tumours
High-volume
(N = 500)
Low-volume
(N = 653)
P-value
High stage, number (%) 360 (72.0) 380 (58.2) <0.001
Low stage, number (%) 49 (9.8) 82 (12.6) 0.
Unknown pT Stage,
number (%)
90 (18.0) 190 (29.1) <0.001
NA, number (%) 1 (0.2) 1 (0.2) 0.850
Peri-ampullary tumours High-volume
(N = 229)
Low-volume
(N = 317)
P-value
High stage, number (%) 123 (53.7) 153 (48.3) 0.209
Low stage, number (%) 95 (41.5) 118 (37.2) 0.144
Unknown pT stage,
number (%)
11 (4.8) 44 (13.9) 0.001
NA, number (%) 0 (0) 2 (0.6) 0.229
Tumour differentiation in all subtypes of malignant tumors
Pancreatic head and
distal bile duct tumours
High-volume
(N = 500)
Low-volume
(N = 653)
P-value
Poorly differentiated,
number (%)
173 (34.6) 163 (25.0) <0.001
Moderately differentiated,
number (%)
186 (37.2) 308 (47.2) 0.001
Well differentiated,
number (%)
46 (9.2) 85 (13.0) 0.043
Unknown differentiation,
number (%)
95 (19.0) 97 (14.9) 0.061
Peri-ampullary tumours High-volume
(N = 229)
Low-volume
(N = 317)
P-value
Poorly differentiated,
number (%)
56 (24.5) 76 (24.0) 0.897
Moderately differentiated,
number (%)
112 (48.9) 152 (47.2) 0.825
Well differentiated,
number (%)
25 (10.9) 29 (9.1) 0.494
Unknown differentiation,
number (%)
36 (15.7) 60 (18.9) 0.331
NA, not applicable.
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In the present study, high-volume hospitals did not report
more R0 resections in peri-ampullary tumours. Peri-ampullary
tumours usually present at an earlier stage and are less bulky
than pancreatic head tumours. It might, therefore, be easier to
remove radically them than it is to remove pancreatic head
tumours. This is reflected in the higher percentage of R0 resec-
tions in papilla and duodenum, as compared with pancreatic
head and distal bile duct tumours, respectively, 82–100%,23–27
46–90%,25,27 41–88%24,25,27,28 and 22–80%.24,25,27,29 It should
be taken in to account that the reported R0 resection rate in
the present study is clearly influenced by the (old) definition
used, not requiring a 1-mm-free margin.
Lastly, in this study most of the distal bile duct tumours
were either a T3/T4 or an unknown stage, therefore, pancreatic
head and distal bile duct tumours were analysed as one group.
This was based on the assumption that when distal bile duct
tumours invade the pancreas it is often difficult to assess the
origin of the primary tumour (i.e. the pancreas or in the distal
bile duct) and therefore patients will often undergo similar
surgical procedures.
The effect of centralization on the reported R0 resection
rates has been scarcely analysed: a recent systematic review10
has shown that institutions with a minimum of 12 PDs per
year achieve higher R0 rates in pancreatic adenocarcinoma
than in centres with lower volumes. This study did, however,
not assess overall resection rates. The achievement of an R0
resection margin is one of the most important prognostic fac-
tors in the treatment of pancreatic head tumours,13–15 thus the
current results suggest that patients treated in high-volume
hospitals may have a better long-term survival in patients with
pancreatic head tumours than those treated in low-volume
hospitals. This is confirmed by two recent studies8,11 that
showed that centralization improves the 2- and 3-year survival
after surgery for pancreatic head tumours.
This study does not show any improvement in the resection
rates of peri-ampullary tumours. To the author’s knowledge, no
other study has analysed the effect of PD volume on the achieve-
ment of R0 resections of peri-ampullary tumours. One study,
however, has shown that centralization improves the
2-year survival after surgery in peri-ampullary tumours.9 Besides
a negative resection margin,26,27,30 other quoted prognostic fac-
tors include: lymph node invasion,23,24,27,30 the use of adjuvant
chemotherapy,28 tumour recurrence24 and histopathological fac-
tors, such as invasion in the pancreas,23 poor differentiation28
and perineural invasion.15 Birkmeyer et al.12 showed that
patients undergoing pancreatic surgery at high-volume hospitals
were more likely to have pre-operative stress tests, invasive peri-
operative monitoring and consultation with medical or radiation
oncologists compared with patients in low-volume hospitals. Pre-
vious studies also showed that high-volume hospitals were more
likely to apply multi-modality therapy in pancreatic adenocarci-
noma.21–23 It is, therefore, possible that the better supportive care
and the use of adjuvant chemotherapy may play a role in the
improvement of the long-term prognosis of peri-ampullary as
pancreatic head tumours in high-volume institutions.
The present study also shows that pathologist in high-vol-
ume hospitals report more lymph nodes during a PD than
low-volume institutions do and that pathology reports in low-
volume institutions lack essential data, such as the pT-, pN
stage and tumour diameter. The optimal histopathological
staging of regional lymph nodes for pancreatic and ampullary
cancer should include at least 10 lymph nodes, for distal bile
duct tumours this number is 3.14 Previous literature has sug-
gested that the analysis of more lymph nodes is an indepen-
dent prognostic factor in the long-term survival.31–34 Two
randomized controlled trials29,35 have shown that extended ret-
roperitoneal lymphadenectomy does not prolong survival but
Table 3 Resection margins for subtypes of malignant tumours
Pancreatic head
and distal bile
duct tumours
High-volume
(N = 500)
Low-volume
(N = 653)
P-value
R0, number (%) 299 (59.8) 350 (53.6) 0.035
R1/R2,
number (%)
183 (36.6) 268 (41.0) 0.126
Unknown
R margin,
number (%)
18 (3.6) 35 (5.4) 0.157
Peri-ampullary High-volume
(N = 229)
Low-volume
(N = 317)
P-value
R0, number (%) 200 (87.3) 277 (87.4) 0.987
R1/R2,
number (%)
20 (8.7) 26 (8.2) 0.825
Unknown
R margin,
number (%)
9 (3.9) 14 (4.4) 0.780
Table 4 Missing data in pathology reports for all malignant tumours
High-volume
(N = 747)
Low-volume
(N = 989)
Total
(N = 1736)
P-value
Unknown R margin, number (%) 19 (2.5) 29 (2.9) 48 (2.8) 0.625
Unknown pT stage, number (%) 111 (14.9) 245 (24.8) 356 (20.5) <0.001
Unknown diameter, number (%) 128 (17.1) 254 (25.7) 382 (22.0) <0.001
Unknown differentiation, number (%) 132 (17.2) 163 (16.2) 295 (16.6) 0.596
Unknown pN stage, number (%) 21 (2.8) 68 (6.9) 89 (5.1) <0.001
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increases morbidity. It is unclear whether the higher mean
number of lymph nodes detected per PD in high-volume hos-
pitals reflects better surgical or better pathology techniques in
these hospitals (or both): surgeons potentially remove more
lymph nodes per procedure and pathologists potentially iden-
tify more lymph nodes in resection specimens.
This does also reflect the importance of ‘high-volume pan-
creatic pathologists’. It is unlikely that pathologists will gain
sufficient experience when they only occasionally assess a pan-
creatoduodenectomy specimen. One suggested solution to this
is central reviewing of pathology samples from several hospitals
as in this way experience can be bundled and expertise
obtained.
The results of this study should be interpreted in light of
some limitations, which are mainly the high percentage of
missing data in the pathology reports, such as tumour stage
(20%) and size (23%). The distribution of the data was also
skewed: there are more missing data for tumour stage and size
in low- than in high-volume hospitals (25% versus 15%, P <
0.001 and 26% versus 17%, P < 0.001, respectively). Impor-
tantly, a recent study36 has shown that owing to an improved,
standardized pathological staging system the R1 resection rate
increased from 14% to 76%, suggesting that an improvement
in experience leads to the detection of more positive resection
margins. Additionally, the Leeds protocol37 that includes multi-
colour margin staining, axial slicing and extensive tissue sam-
pling also improves the reporting of R1 resection margins. It
is, therefore, possible that some of the observed differences in
the resection rates of high and low-volume hospitals may be in
fact be underestimated. This study underlines the importance
of centralization of pancreatic surgery: it improves not only
surgical expertise but also that of supporting specializations.
Another limitation of this study is the lack of correlation
with post-operative mortality and survival data. However, mul-
tiple previous Dutch studies have already shown that through-
out the same period (2005–2009) post-operative mortality
decreased (from 9.8% to 5.1%) whereas the 2-year survival
increased.7,8
In conclusion, in a period where centralization of pancreatic
surgery occurred, the annual volume of PDs carried out for
malignant tumours in the Netherlands increased by 56%. This is
largely explained by higher resection rates. Although high-
volume hospitals operated on more advanced and poorly
differentiated pancreatic tumours, they reported more R0 resec-
tions in tumours of the pancreatic head. The exact impact of this
finding on overall survival should be assessed in future studies.
Finally, pathology reports of low-volume hospitals more often
lacked essential data. Thus pathology reports should be stan-
dardized in order to minimize missing data.
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